# A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics

> **NCT02960490** · PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 66 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** E6011
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02960490
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-26
- **Primary completion:** 2018-05-16
- **Final completion:** 2019-11-25
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960490, "A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02960490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*